Drug helps brain tumor patients live longer

January 28, 2008

People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to research published in the January 29, 2008, issue of Neurology.

“Our findings show high-dose methotrexate alone or in combination with other chemotherapy drugs is the most effective treatment available for primary central nervous system lymphoma (PCNSL)” said study author Tracy Batchelor, MD, with the Massachusetts General Hospital Cancer Center in Boston. PCNSL can be a potentially curable brain tumor or one in which there can be a long remission.

The research involved 25 adults with newly diagnosed PCNSL who received a high dose of methotrexate every two weeks for four months or until there were no signs of the brain tumor. The participants were then followed for a minimum of 6.5 years.

The article found 52 percent of the participants achieved complete remission and 40 percent of these patients have not relapsed after an average of seven years. The average survival rate of all participants who received methotrexate was 4.5 years. In contrast, the average survival rate for patients who receive radiation therapy for this type of brain tumor is one year.

“Our findings support the role of methotrexate as a critical chemotherapy drug in the treatment of this type of brain tumor,” said Batchelor. “Moreover, it appears some people may achieve a long remission through the methotrexate alone.”

Batchelor says further studies are needed to identify the optimal methotrexate dose and combination therapy that will produce the most effective results with minimum side effects.

Source: American Academy of Neurology

Explore further: Team moves small-molecule drugs through blood-brain barrier

Related Stories

Team moves small-molecule drugs through blood-brain barrier

June 4, 2014

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. ...

Recommended for you

Universal flu vaccine designed by scientists

September 30, 2016

An international team of scientists have designed a new generation of universal flu vaccines to protect against future global pandemics that could kill millions.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.